Radboud University Medical Center: Melanoma trials

The registry lists 13 Melanoma studies with Radboud University Medical Center as lead sponsor. 2 are open to participants now and 0 have results posted.

Phase 1 8Phase 2 10Phase 3 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Timing of Immunotherapy in MelanomaRecruitingNCT07696715Not applicable
• Dietary Fiber to Induce Gut Microbiota-mediated Response to Immunotherapy in Melanoma.RecruitingNCT07686835Phase 2
• Melanoma Patients Immunized with Natural DenDritic CellsCompletedNCT02993315Phase 3
• Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab TherapyStatus unknownNCT02968303Phase 2
• myDC/pDC in Stage III Melanoma PatientsCompletedNCT02574377Phase 1/2
• Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma PatientsCompletedNCT02285413Phase 2
• Natural Dendritic Cell Vaccines in Metastatic Melanoma PatientsCompletedNCT01690377Phase 1
• Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma PatientsCompletedNCT01530698Phase 1/2
• Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma PatientsCompletedNCT00940004Phase 1/2
• Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma PatientsTerminatedNCT00929019Phase 1/2
• Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma PatientsCompletedNCT00847106Phase 1/2
• Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node DissectionCompletedNCT00243594Phase 1/2
• Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma PatientsCompletedNCT00243529Phase 1/2